Evidence map›Paper›PMID 39343173›Full record

Trial reportThe Journal of allergy and clinical immunology2025

CERS1 is a biomarker of Staphylococcus aureus abundance and atopic dermatitis severity.

H Mark Kenney, Takeshi Yoshida, Evgeny Berdyshev, Agustin Calatroni, Steven R Gill, Eric L Simpson, Stephanie Lussier, Mark Boguniewicz, Tissa Hata, Zelma C Chiesa Fuxench and 8 more

Registry-linked trialAbstract readClinical Trial, Phase IVMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of allergy and clinical immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03389893 (Effect of Dupilumab), which is not on this map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03389893 phase4terminatednot on this map

Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis, Dupilumab Study

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2018 to 2020Enrolled72ConditionsAtopic Dermatitis (AD)ArmsDupilumab, Placebo
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

H Mark KenneyDepartment of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY.
Takeshi YoshidaDepartment of Dermatology, University of Rochester Medical Center, Rochester, NY.
Evgeny BerdyshevDepartment of Medicine, National Jewish Health and University of Colorado School of Medicine, Denver, Colo.
Agustin CalatroniRho Inc, Durham, NC.
Steven R GillDepartment of Microbiology & Immunology, University of Rochester Medical Center, Rochester, NY.
Eric L SimpsonDepartment of Dermatology, Oregon Health and Science University, Portland, Ore.
Stephanie LussierRho Inc, Durham, NC.
Mark BoguniewiczDivision of Allergy-Immunology, Department of Pediatrics, National Jewish Health and University of Colorado School of Medicine, Denver, Colo.
Tissa HataDepartment of Dermatology, University of California, San Diego, Calif.
Zelma C Chiesa FuxenchDepartment of Dermatology, University of Pennsylvania, Philadelphia, Pa.
Anna De BenedettoDepartment of Dermatology, University of Rochester Medical Center, Rochester, NY.
Peck Y OngDepartment of Pediatrics, University of Southern California, Division of Clinical Immunology and Allergy Children's Hospital Los Angeles, Los Angeles, Calif.
Justin KoDepartment of Dermatology, Stanford University, Stanford, Calif.
Wendy DavidsonDivision of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
Gloria DavidRho Inc, Durham, NC.
Patrick M SchlievertDepartment of Microbiology and Immunology, University of Iowa, Iowa City, Iowa.
Donald Y M LeungDivision of Allergy-Immunology, Department of Pediatrics, National Jewish Health and University of Colorado School of Medicine, Denver, Colo.
Lisa A BeckDepartment of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY; Department of Dermatology, University of Rochester Medical Center, Rochester, NY. Electronic address: lisa_beck@urmc.rochester.edu.

Funding

Transplantation GroupUM2AI117870 · NIAID · RHO FEDERAL SYSTEMS DIVISION, INC. · PI DAVID, GLORIA · 2015 to 2023
$208.1M
Experimental and Computational Analysis of the Human Epidemiology and Response to SARS-CoV-2 (HEROS) CohortUM1AI151958 · NIAID · NATIONAL JEWISH HEALTH · PI Donald YM Leung · 2020 to 2026
$38.3M
RhoFED AA-SCCCU01AI178772 · NIAID · RHO FEDERAL SYSTEMS DIVISION, INC. · PI Gloria David, Cynthia M Visness · 2023 to 2026
$37.2M
Colorado Clinical and Translational Sciences Institute (CCTSI)UM1TR004399 · NCATS · UNIVERSITY OF COLORADO DENVER · PI JANINE A HIGGINS, RONALD J. SOKOL · 2023 to 2026
$30.7M
Targeted Microbiome Transplant in Atopic DermatitisU19AI117673 · NIAID · NATIONAL JEWISH HEALTH · PI GALLO, RICHARD L · 2015 to 2019
$30.6M
University of Rochester Mentoring Environment: Nurturing Training Opportunities in Research (UR-MENTOR)T32GM007356 · NIGMS · UNIVERSITY OF ROCHESTER · PI O'BANION, M. KERRY · 1985 to 2023
$15.1M
Biomarker Identification, Viral Susceptibility and Management in S. aureus Colonized AD PatientsU01AI152011 · NIAID · UNIVERSITY OF ROCHESTER · PI Lisa Ann Beck · 2020 to 2026
$3.2M
Elucidating the Mechanisms of Lymphatic Muscle Cell Dysfunction in Aging and InflammationF30AG076326 · NIA · UNIVERSITY OF ROCHESTER · PI KENNEY, HOWARD MARK · 2022 to 2023
$98k
NCATS NIH HHS UM1 TR004399NIAID NIH HHS U01 AI152011NIAID NIH HHS U01 AI178772NIAID NIH HHS U19 AI117673NIAID NIH HHS UM1 AI151958NIAID NIH HHS UM2 AI117870NIA NIH HHS F30 AG076326NIGMS NIH HHS T32 GM007356
6 · The paper itself

Abstract

backgroundAtopic dermatitis (AD) is an inflammatory skin condition characterized by widely variable cutaneous Staphylococcus aureus abundance that contributes to disease severity and rapidly responds to type 2 immune blockade (ie, dupilumab). The molecular mechanisms regulating S aureus levels between AD subjects remain poorly understood.

objectiveWe investigated host genes that may be predictive of S aureus abundance and correspond with AD severity.

methodsWe studied data derived from the National Institutes of Health/National Institute of Allergy and Infectious Diseases-funded (NCT03389893 [ADRN-09]) randomized, double-blind, placebo-controlled multicenter study of dupilumab in adults (n = 71 subjects) with moderate-to-severe AD. Bulk RNA sequencing of skin biopsy samples (n = 57 lesional, 55 nonlesional) was compared to epidermal S aureus abundance, lipidomic, and AD clinical measures.

resultsS aureus abundance and ceramide synthase 1 (CERS1) expression positively correlated at baseline across both nonlesional (r = 0.29, P = .030) and lesional (r = 0.41, P = .0015) skin. Lesional CERS1 expression also positively correlated with AD severity (ie, SCORAD r = 0.44, P = .0006) and skin barrier dysfunction (transepidermal water loss area under the curve r = 0.31, P = .025) at baseline. CERS1 expression (forms C

conclusionCERS1 is a unique molecular biomarker of S aureus abundance and AD severity that may contribute to dysfunctional skin barrier and shorter-chain sphingolipid composition through fatty acid sequestration as a maladaptive compensatory response to reduced ELOVL6.

Indexed as

Dermatitis, AtopicSphingosine N-AcyltransferaseStaphylococcus aureusAdultAntibodies, Monoclonal, HumanizedBiomarkersDouble-Blind MethodFemaleHumansMaleMembrane ProteinsMiddle AgedSeverity of Illness IndexSkinAntibodies, Monoclonal, HumanizedBiomarkersCERS1 protein, humandupilumabMembrane ProteinsSphingosine N-AcyltransferaseAtopic dermatitisceramide synthaseCERS1dupilumabmicrobiomeskin barriersphingolipidsStaphylococcus aureustranscriptomicstype 2 immunity

Identifiers

PMID39343173
PMCPMC11805642

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.